Skip to main content

Oncology Precision Medicine : A Concept of Identifying Specific Genes

 The human genome comprises DNA sequences that provide a code for the synthesis and regulation of an estimated 20,000 proteins. However, there is a natural variation between individuals’ genomes that leads to differences in structure, function, and production of proteins. Precision medicine is a concept of identifying such variations in specific genes that affect the health response to interventions. Contrary to the empiric medicine method, the precision medicine approach begins with testing and analysis of the patient to pre-determine the best fit mode of treatment for the patient. Following the accomplishment of the human genome project, there had been significant progress in characterizing the human epigenome, proteome, metabolome, and pharmacogenomics that has led to the evolution of customized healthcare for the individual, especially patients suffering from cancer. 

View BIS Research Report on Oncology Precision Medicine Market


Furthermore, germline mutations and somatic mutations are critical in driving cancer imitation or progression and thus the study of structural variations via sequencing or other molecular diagnostic techniques, which have been an integral part of precision medicine and may help in the early-stage screening of the disease. Moreover, precise screening also allows targeted therapy, which has a significant role in cancer treatment as through this mode, cancer cell growth can be blocked via interfering with the targeted molecules that are involved in cancer. Further, with the global expansion of cancer incidences at such a rapid rate, there has been a demand for alternative medicine other than the traditional one. Hence, the aforementioned factors have posed a necessity for an effective treatment method that involves the precision medicine approach.


Request for free Sample: https://bisresearch.com/requestsample?id=1026&type=download


About BIS Research:

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends that are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials, and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

What distinguishes BIS Research from the rest of the players is that we don’t simply provide data but also complement it with valuable insights and actionable inputs for the success of our clients.


Comments

Popular posts from this blog

Chatbots Increasing Efficiency in Healthcare Market

Chatbots are one of the prominent technologies currently being integrated into the healthcare system. The chatbots are not considered as the SaMD (software as medical device) as they do not participate in clinical decision-making process, rather, they act as the personal healthcare assistant as well as the trainer for its users. Click Here To Get Detailed Description of  Chatbots in Healthcare Market The usage of chatbots in the healthcare has gained popularity since 2013, when Babylon Health, the first healthcare chatbot company of the U.K. was launched. The company offered symptom checker chatbot and has started using the same chatbot as a health checker as well. The industry comprises the bot developers, platform providers, content providers, and the interface providers. Since there are no regulatory bodies such as FDA and MHRA directly governing the usage of chatbots, launching the chatbot is convenient for the developers. New start-ups are coming up wit...

Wireless Charging Technology – Analyzing the Market Drivers and Restraints

Wireless charging technology eliminates the use of wires to power devices and enables a device to be charged automatically when placed near a transmitter. The wireless charging technology is however, not new in the world of technology, rather, has been in existence since the late 1800s. With the incorporation of the technology in smartphones, it has been experiencing a massive boost in popularity. Request the Sample @  https://bisresearch.com/requestsample?id=645&type=download According to the latest market intelligence report by BIS Research titled “ Global Wireless Charging Market - Analysis and Forecast (2018-2023) ,” the market was valued at $2.58 billion in 2017 and is projected to grow at a CAGR of 40.97%, during the forecast period and reach $20.97 billion by 2023.  The market is estimated to witness the highest growth in the Asia-Pacific (APAC) region during the forecast period (2018-2023). The wireless charging technology is not only limited to the sm...

Neoantigens Vaccines Can Bridge the Treatment Gap by Training the Immune System to Recognize Tumor Cells

As per BIS Research analysis, the neoantigen cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1 million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven by the ever-rising patient pool of different cancers and significant investment in research for development for cancer neoantigen vaccines to fill in the current treatment gaps. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of therapy (personalized cancer vaccines), manufacturing complications, and lack of therapeutic biomarkers and assays. The market is still at the nascent phase with more than two-thirds of the neovaccines in the early stages of development. However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, and Roche have positioned themselves to launch their neovaccines in the market within the upcoming years. That being said, the neovacc...